Associated Papers
Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase.
Freire TS et al.
Physical Chemistry Chemical Physics : Pccp, 2023
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
Ferng TT et al.
Molecular Cancer Therapeutics, 2022
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.
Ge SS et al.
Frontiers in Oncology, 2022
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Joshi SK et al.
American Journal of Hematology, 2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mizuta H et al.
Nature Communications, 2021
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver TC et al.
Blood Advances, 2020
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J et al.
Cancer Research, 2004
Select a paper to view details